Overview

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

Status:
Terminated
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Etidronic Acid
Hormones
Raloxifene Hydrochloride
Risedronate Sodium
Risedronic Acid